Dublin, Nov. 14, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/zps5nt/asiapacific) has announced the addition of the "Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017" report to their offering.
The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (Japan, China, India, South Korea, Malaysia, Indonesia, Australia, New Zealand, and Rest of Asia) to provide in-depth information on the Asia-Pacific scenario.
The radiopharmaceuticals market in the Asia-Pacific region was valued at $500.8 million in 2012; it is poised to reach $824.9million in 2017 at a CAGR of 10.5%.
The market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 80.7% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium-201(Tl-201), gallium-67 (Ga-67), and iodine-123 (I-123). SPECT is majorly used in cardiology-related diagnosis; it is poised to grow at a CAGR of 10.2% from 2012 to 2017. The PET radioisotopes market is dominated by fluoride-18 (F-18), followed by rubidium-82 (Rb-82).
Segments in the therapeutic market are beta emitters, brachytherapy isotopes, and alpha emitters. Quantitative information about alpha emitters has not been arrived at, as they have not been commercialized; recent clinical studies have, however, showcased immense potential of alpha isotopes in therapies. Beta emitters contribute the highest to the therapy market, dominated by iodine-131(I-131), which is poised to grow at a CAGR of 7.7% from 2012 to 2017. The Asia-Pacific market is driven by its applications for thyroid cancer, hyperthyroidism, and non-Hodgkin's lymphoma. Significant isotopes in the brachytherapy market are cesium-131(Cs-131), iodine-125 (I-125), palladium-103 (Pd-103), and iridium-192 (Ir-192).
Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are boosting the growth of the Asia-Pacific nuclear medicine market. Upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The nuclear disaster at Fukushima nuclear plants in 2011 had a major impact on radioisotope production in Japan, which is the largest consumer market in the Asia-Pacific region. The Asia-Pacific region is insulated from the global crisis in Mo-99 supply since the production is based on local nuclear plants and OPAL reactor of ANSTO. ANSTO is deemed as the future solution to compensate global Mo-99 demand.
Major players in the radiopharmaceuticals market are Nihon Medi-Physics Co., Ltd. (Japan), Covidien PLC (U.S.), Fujifilm Corporation (Japan), ANSTO (Australia), and IBA S.A (Belgium).
The Asia-Pacific stable isotopes market is dominated by deuterium (D2), oxygen-18 (O-18), carbon-13 (C-13), and nitrogen-15 (N-15). Research, pharmaceuticals, diagnostic and therapy, and industries are major applications. The Asia-Pacific stable isotopes market was estimated at $56.1 million in 2012 and is expected to cross $100.0 million by 2017 at a CAGR of 12.6%.
The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.) and Sigma Aldrich (U.S.) in 2012.
Key Topics Covered:
2 Executive Summary
3 Market Overview
4 Asia-Pacific Radiopharmaceuticals Market, By Isotope
5 Asia-Pacific Radiopharmaceuticals Market, By Application/Indication
6 Asia-Pacific Enriched Stable Isotopes Market
7 Geographic Analysis
8 Competitive Landscape
9 Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)*
9.1 Bracco Imaging S.P.A.
9.2 Cambridge Isotope Laboratories, Inc.
9.3 Cardinal Health, Inc.
9.4 Covidien, Plc
9.6 Fujifilm Holdings Corporation
9.7 Ge Healthcare (Subsidiary Of General Electric Company)
9.8 Iba Group
9.9 Isotec, Inc. (Sigma-Aldrich)
9.10 Lantheus Medical Imaging, Inc.
9.11 Nordion, Inc.
9.12 Ntp Radioisotopes (Pty), Ltd.
9.13 Siemens Healthcare (Subsidiary Of Siemens AG)
9.14 Taiyo Nippon Sanso Corporation
9.15 Urenco Limited
9.16 Rotem Industries, Ltd., Inc.
9.17 Australian Nuclear Association And Technology Organization (ANSTO)
9.18 Board Of Radiation And Isotope Technology (BRIT)
9.19 Institute Of Atomic Energy Polatom Radioisotope Centre
9.20 Institute Of Isotopes Co., Ltd.
9.21 Institute Of Radioelement (IRE)
For more information visit http://www.researchandmarkets.com/research/zps5nt/asiapacific
Source:Research and Markets